Carmen Berasain

List of Publications by Year
in descending order

137 papers	6,446 citations	66315 42 h-index	69214 77 g-index
138 all docs	138 docs citations	138 times ranked	9255 citing authors

#	Article	IF	Citations
1	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut, 2022, 71, 1141-1151.	6.1	32
2	A new animal model of atrophyâ€"hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits. Scientific Reports, 2022, 12, 1777.	1.6	3
3	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. British Journal of Cancer, 2022, 126, 1783-1794.	2.9	12
4	Impact of Alternative Splicing Variants on Liver Cancer Biology. Cancers, 2022, 14, 18.	1.7	11
5	Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers, 2022, 14, 78.	1.7	3
6	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. Cancers, 2022, 14, 2048.	1.7	5
7	The Amphiregulin/EGFR axis protects from lupus nephritis via downregulation of pathogenic CD4+ T helper cell responses. Journal of Autoimmunity, 2022, 129, 102829.	3.0	5
8	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	9
9	Dual Targeting of G9a and DNA Methyltransferaseâ€1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology, 2021, 73, 2380-2396.	3.6	26
10	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut, 2021, 70, gutjnl-2019-320205.	6.1	36
11	Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position?. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 291-293.	2.3	1
12	FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Molecular Metabolism, 2021, 43, 101113.	3.0	18
13	ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity. Cancers, 2021, 13, 1110.	1.7	7
14	Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers, 2021, 13, 1265.	1.7	23
15	PHAROH lncRNA regulates Myc translation in hepatocellular carcinoma via sequestering TIAR. ELife, 2021, 10, .	2.8	18
16	The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation. Nucleic Acids Research, 2021, 49, 8592-8609.	6.5	2
17	Splicing Factor SLU7 Prevents Oxidative Stressâ€Mediated Hepatocyte Nuclear Factor 4Î± Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology, 2021, 74, 2791-2807.	3.6	12
18	Chromatin dynamics during liver regeneration. Seminars in Cell and Developmental Biology, 2020, 97, 38-46.	2.3	10

#	Article	IF	Citations
19	Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. International Journal of Molecular Sciences, 2020, 21, 5500.	1.8	25
20	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Reports, 2020, 2, 100167.	2.6	51
21	Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?. Cells, 2020, 9, 2321.	1.8	21
22	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 2020, 12, 3748.	1.7	6
23	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	1.7	38
24	Amphiregulin Aggravates Glomerulonephritis via Recruitment and Activation of Myeloid Cells. Journal of the American Society of Nephrology: JASN, 2020, 31, 1996-2012.	3.0	14
25	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	15
26	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	3.6	81
27	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	5.8	124
28	PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Journal of Hepatology, 2019, 70, e27-e28.	1.8	1
29	THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins. Journal of Hepatology, 2019, 70, e365-e366.	1.8	0
30	THU-064-Identification of new epigenetic targets in hepatic fibrosis. Journal of Hepatology, 2019, 70, e188.	1.8	0
31	Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box Against Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 293-294.	2.3	15
32	Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins. Nucleic Acids Research, 2019, 47, 3450-3466.	6.5	53
33	Hepatocyte-specific deletion of ERK5 modulates liver regeneration in mice. Digestive and Liver Disease, 2019, 51, e43.	0.4	0
34	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology, 2019, 69, 1632-1647.	3.6	42
35	LKB1: Controlling Quiescence and Genomic Integrity at Home. Trends in Endocrinology and Metabolism, 2018, 29, 668-670.	3.1	1
36	Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1326-1334.	1.8	34

#	Article	IF	Citations
37	Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. Translational Gastroenterology and Hepatology, 2018, 3, 84-84.	1.5	14
38	Fibroblast growth factors 19 and 21 in acute liver damage. Annals of Translational Medicine, 2018, 6, 257-257.	0.7	11
39	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. Cell Death and Disease, 2018, 9, 958.	2.7	38
40	Novel role of amphiregulin in bile acids metabolism and protection from cholestatic liver injury. Journal of Hepatology, 2018, 68, S74.	1.8	0
41	Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut, 2017, 66, 1818-1828.	6.1	118
42	Targeting the correct target in HCC. Gut, 2017, 66, 1352-1354.	6.1	10
43	Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis. Digestive Diseases, 2017, 35, 158-165.	0.8	35
44	Development of novel epigenetic inhibitors for the treatment of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S76-S77.	1.8	0
45	SLU7 is a survival factor for cancer cells working as a mitotic regulator. Journal of Hepatology, 2017, 66, S645.	1.8	0
46	ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. Journal of Hepatology, 2017, 66, 581-588.	1.8	43
47	Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death and Disease, 2017, 8, e3083-e3083.	2.7	17
48	Further evidence on the janusâ€faced nature of the epidermal growth factor receptor: From liver regeneration to hepatocarcinogenesis. Hepatology, 2016, 63, 371-374.	3.6	2
49	New molecular interactions of câ€Myc in cholangiocarcinoma may open new therapeutic opportunities. Hepatology, 2016, 64, 336-339.	3.6	3
50	Development of a New Hepatoprotective and Proregenerative Molecule Based on Fibroblast Growth Factor 15/19. Journal of Hepatology, 2016, 64, S184.	1.8	2
51	Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. Oncogene, 2016, 35, 4719-4729.	2.6	27
52	Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget, 2016, 7, 49194-49216.	0.8	20
53	Conflicting relationship between platelets and prognosis of hepatocellular carcinoma: is plateletâ€derived serotonin involved in?. Liver International, 2015, 35, 2484-2484.	1.9	8
54	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/Câ€Xâ€C chemokine receptor 4 axis. Hepatology, 2015, 62, 166-178.	3.6	61

#	Article	IF	Citations
55	Oxidative Stress Mechanisms in Hepatocarcinogenesis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 449-477.	0.4	0
56	Ileal <scp>FGF</scp>15 contributes to fibrosisâ€associated hepatocellular carcinoma development. International Journal of Cancer, 2015, 136, 2469-2475.	2.3	79
57	Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14. Hepatology, 2015, 61, 1755-1757.	3.6	16
58	O096 : Matrix metalloproteinase-10 contributes to hepatocellular carcinoma development in a novel crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis. Journal of Hepatology, 2015, 62, S242.	1.8	0
59	Regulation of hepatocyte identity and quiescence. Cellular and Molecular Life Sciences, 2015, 72, 3831-3851.	2.4	38
60	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver International, 2015, 35, 1590-1596.	1.9	55
61	Deciphering liver zonation: New insights into the Î²-catenin, Tcf4, and HNF4Î± triad. Hepatology, 2014, 59, 2080-2082.	3.6	21
62	Amphiregulin. Seminars in Cell and Developmental Biology, 2014, 28, 31-41.	2.3	213
63	The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. Journal of Gastroenterology, 2014, 49, 9-23.	2.3	129
64	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
65	Alterations in the expression and activity of pre-mRNA splicing factors in hepatocarcinogenesis. Hepatic Oncology, 2014, 1, 241-252.	4.2	9
66	New mechanisms involving the EGFR and FGF15/19 systems in liver regeneration and carcinogenesis. European Journal of Medical Research, 2014, 19, .	0.9	0
67	O152 THE SPLICING FACTOR SLU7 IS ESSENTIAL FOR THE PRESERVATION OF LIVER DIFFERENTIATION, METABOLIC FUNCTION AND QUIESCENCE. Journal of Hepatology, 2014, 60, S63.	1.8	0
68	P62 MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION. Journal of Hepatology, 2014, 60, S87.	1.8	0
69	O97 GUT-DERIVED FGF15 PLAYS A CENTRAL ROLE IN FIBROSIS-ASSOCIATED HEPATOCARCINOGENESIS. Journal of Hepatology, 2014, 60, S40.	1.8	0
70	Splicing regulator SLU7 is essential for maintaining liver homeostasis. Journal of Clinical Investigation, 2014, 124, 2909-2920.	3.9	55
71	Amphiregulin. , 2014, , 204-207.		0
72	Amphiregulin. , 2014, , 1-4.		0

#	Article	IF	Citations
73	Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?. Gut, 2013, 62, 1674-1675.	6.1	82
74	300 IDENTIFICATION OF MATRIX METALLOPROTEASE 10 (MMP10) AS A KEY NEW MEDIATOR OF THE REGENERATIVE RESPONSE OF THE LIVER. Journal of Hepatology, 2013, 58, S126.	1.8	0
75	86 REGULATION OF ALTERNATIVE SPLICING BY SLU7 IS ESSENTIAL FOR HCC CELL SURVIVAL. Journal of Hepatology, 2013, 58, S38.	1.8	0
76	Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut, 2013, 62, 899-910.	6.1	163
77	Platelet-derived growth factor D: A new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts. Hepatology, 2013, 58, 853-855.	3.6	6
78	66 CONTROL OF BILE ACIDS LEVELS BY FGF15 IS ESSENTIAL FOR NORMAL LIVER REGENERATION AFTER PARTIAL HEPATECTOMY. Journal of Hepatology, 2012, 56, S29.	1.8	0
79	Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. Journal of Hepatology, 2012, 56, 367-373.	1.8	43
80	Epidermal Growth Factor Receptor Signaling in Hepatocellular Carcinoma: Inflammatory Activation and a New Intracellular Regulatory Mechanism. Digestive Diseases, 2012, 30, 524-531.	0.8	41
81	Regulation of Amphiregulin Gene Expression by Î²-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS ONE, 2012, 7, e52711.	1.1	45
82	Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers, 2011, 3, 2444-2461.	1.7	65
83	Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. Journal of Hepatology, 2011, 55, 828-837.	1.8	14
84	Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology, 2011, 54, 2149-2158.	3.6	108
85	AREG (amphiregulin (schwannoma-derived growth factor)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
86	Amphiregulin. , 2011, , 158-160.		0
87	New therapeutic targets in HCC: Reptin ATPase and HCC senescence. Journal of Hepatology, 2010, 52, 633-634.	1.8	8
88	Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2â^'/â^' Mice. PLoS ONE, 2010, 5, e15690.	1.1	23
89	Impairment of pre-mRNA splicing in liver disease: Mechanisms and consequences. World Journal of Gastroenterology, 2010, 16, 3091.	1.4	40
90	Wilms' Tumor 1 Gene Expression in Hepatocellular Carcinoma Promotes Cell Dedifferentiation and Resistance to Chemotherapy. Cancer Research, 2009, 69, 1358-1367.	0.4	46

#	Article	IF	Citations
91	<i>In vivo</i> depletion of DC impairs the antiâ€tumor effect of agonistic antiâ€CD137 mAb. European Journal of Immunology, 2009, 39, 2424-2436.	1.6	47
92	Inflammation and Liver Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 206-221.	1.8	329
93	The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. Journal of Hepatology, 2009, 51, 1010-1020.	1.8	17
94	Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform Î”Ex2p73 in Human Hepatocellular Tumors. Gastroenterology, 2009, 137, 1805-1815.e4.	0.6	64
95	The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer. Experimental Biology and Medicine, 2009, 234, 713-725.	1.1	107
96	46 TREATMENT OF EXPERIMENTAL FULMINANT HEPATIC FAILURE (FHF) BY ENDOTELIAL PROGENITOR CELLS (EPC) TRANSDUCED BY AN ADENOVIRUS ENCODING CARDIOTROPHIN-1 (CT-1). Journal of Hepatology, 2009, 50, S19-S20.	1.8	0
97	The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology, 2008, 48, 1251-1261.	3.6	124
98	Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Therapy, 2008, 15, 473-483.	2.3	20
99	Novel Pharmacologic Strategies to Protect the Liver from Ischemia- Reperfusion Injury. Recent Patents on Cardiovascular Drug Discovery, 2008, 3, 9-18.	1.5	16
100	Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochemical and Biophysical Research Communications, 2007, 364, 92-99.	1.0	12
101	106 Interferon-Producing Killer Dendritic Cells and Natural Killer Cells Response to Interleukin-15 Liver Gene Transfer. Cytokine, 2007, 39, 29.	1.4	0
102	Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Letters, 2007, 254, 30-41.	3.2	80
103	[73] AMPHIREGULIN INDUCES THE EXPRESSION OF ONCOGENIC ISOFORMS OF P73 IN HOC THROUGH THE MODULATION OF ITS ALTERNATIVE SPLICING. Journal of Hepatology, 2007, 46, S33.	1.8	0
104	[330] AMPHIREGULIN, A GROWTH FACTOR OF THE EGF FAMILY, PARTICIPATES IN THE DEVELOPMENT OF LIVER FIBROSIS. Journal of Hepatology, 2007, 46, S130.	1.8	0
105	New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver International, 2007, 27, 174-185.	1.9	59
106	Immunotherapy and immunoescape in colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5822.	1.4	36
107	Molecular Profiling of Hepatocellular Carcinoma in Mice with a Chronic Deficiency of HepaticS-Adenosylmethionine:Â Relevance in Human Liver Diseases. Journal of Proteome Research, 2006, 5, 944-953.	1.8	18
108	350 Amphiregulin a novel determinant in the resistance of HCC cells to apoptosis induced by TGF-Î² and cytostatic drugs. Journal of Hepatology, 2006, 44, S134.	1.8	0

#	Article	IF	Citations
109	Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. Journal of Hepatology, 2006, 44, 537-543.	1.8	88
110	New therapies for hepatocellular carcinoma. Oncogene, 2006, 25, 3866-3884.	2.6	362
111	Methylthioadenosine reverses brain autoimmune disease. Annals of Neurology, 2006, 60, 323-334.	2.8	65
112	Differential regulation of the JNK/AP-1 pathway by S-adenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells. American Journal of Physiology - Renal Physiology, 2006, 290, G1186-G1193.	1.6	11
113	Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. Journal of Experimental Medicine, 2006, 203, 2809-2815.	4.2	62
114	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Research, 2006, 66, 2442-2450.	0.4	129
115	Amphiregulin Contributes to the Transformed Phenotype of Human Hepatocellular Carcinoma Cells. Cancer Research, 2006, 66, 6129-6138.	0.4	125
116	Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 267-281.	1.7	18
117	Novel Role for Amphiregulin in Protection from Liver Injury. Journal of Biological Chemistry, 2005, 280, 19012-19020.	1.6	115
118	Hepatitis C virus infection of primary tupaia hepatocytes leads to selection of quasispecies variants, induction of interferon-stimulated genes and NF-ÎºB nuclear translocation. Journal of General Virology, 2005, 86, 3065-3074.	1.3	18
119	Amphiregulin: An early trigger of liver regeneration in mice. Gastroenterology, 2005, 128, 424-432.	0.6	173
120	5â€²-methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology, 2004, 39, 1088-1098.	3.6	91
121	Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 276-284.	1.8	32
122	177 5â€²-Methylthioadenosine modulates the inflammatory response to bacterial lipopolysaccharide. Journal of Hepatology, 2004, 40, 58.	1.8	0
123	Expression of Wilms' tumor suppressor in the liver with cirrhosis: Relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology, 2003, 38, 148-157.	3.6	56
124	SarA and not ÏƒB is essential for biofilm development by Staphylococcus aureus. Molecular Microbiology, 2003, 48, 1075-1087.	1.2	400
125	The Wilms' tumor suppressor: A developmental-restricted factor reexpressed in liver cirrhosis. Journal of Hepatology, 2003, 38, 74-75.	1.8	1
126	Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I. International Journal of Biochemistry and Cell Biology, 2002, 34, 242-252.	1.2	40

#	Article	IF	Citations
127	Genetic analysis ofSalmonella enteritidisbiofilm formation: critical role of cellulose. Molecular Microbiology, 2002, 43, 793-808.	1.2	462
128	Hyperhomocysteinemia in Liver Cirrhosis. Hypertension, 2001, 38, 1217-1221.	1.3	97
129	Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut, 2000, 47, 429-435.	6.1	112
130	Sâ€Adenosylmethionine regulatesMAT1AandMAT2Agene expression in cultured rat hepatocytes: a new role for Sâ€adenosylmethionine in the maintenance of the differentiated status of the liver. FASEB Journal, 2000, 14, 2511-2518.	0.2	102
131	Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2000, 33, 907-914.	1.8	315
132	Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma: A novel role for S-adenosylmethionine. Journal of Hepatology, 2000, 32, 209.	1.8	1
133	Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA.. Journal of General Virology, 1999, 80, 727-738.	1.3	23
134	Oncogenic activation of a human cyclinâ€‰A2 targeted to the endoplasmic reticulum upon Hepatitisâ€‰B virus genome insertion. Oncogene, 1998, 16, 1277-1288.	2.6	44
135	Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity. European Journal of Immunology, 1995, 25, 877-883.	1.6	48
136	Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine, 1994, 12, 867-871.	1.7	15
137	Detection of anti-hepatitis C virus antibodies by ELISA using synthetic peptides. Journal of Hepatology, 1993, 18, 80-84.	1.8	7